Genentech/Curis To Reformulate Basal Cell Carcinoma Topical Treatment
This article was originally published in The Pink Sheet Daily
Preliminary Phase I results show histological clearance, but less clinical activity than anticipated with Hedgehog antagonist, Curis says.
You may also be interested in...
Cambridge, Mass.-based Curis seeks a new partner to continue small molecule and protein hedgehog agonist development in cardiovascular/nervous system disorders.
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.